Table 2 Survival analysis by univariate and multivariate methods to identify prognostic factors in HCC
From: SESN2 correlates with advantageous prognosis in hepatocellular carcinoma
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
HR | p value | 95% CI | HR | p value | 95% CI | |
SESN2 expression | ||||||
High versus Low | 0.271 | 0.001* | 0.136–0.542 | 0.308 | 0.003* | 0.140–0.678 |
Gender | ||||||
Male versus Female | 1.140 | 0.732 | 0.539–2.414 | |||
Age (years) | ||||||
< 60 versus ≥60 | 1.630 | 0.084 | 0.937–2.838 | |||
Hepatitis B virus infection | ||||||
Positive versus Negative | 1.111 | 0.900 | 0.526–1.539 | |||
Hepatitis C virus infection | ||||||
Positive versus Negative | 1.799 | 0.036* | 1.039–3.114 | 0.940 | 0.851 | 0.493–1.793 |
Liver cirrhosis | ||||||
Positive versus Negative | 1.137 | 0.644 | 0.660–1.959 | |||
Tumour size (cm) | ||||||
> 5 versus ≤5 | 1.412 | 0.219 | 0.814–2.449 | |||
Lymph node metastasis | ||||||
Positive versus Negative | 2.795 | 0.001* | 1.621–4.821 | 1.839 | 0.063 | 0.968–3.495 |
Distant metastasis | ||||||
Positive versus Negative | 2.709 | 0.003* | 1.417–5.179 | 0.925 | 0.846 | 0.421–2.033 |
TNM stage | ||||||
Stage I-II versus Stage III-IV | 0.276 | 0.001* | 0.144–0.527 | 0.352 | 0.003* | 0.178–0.696 |